Almirall SA operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Almirall SA with three other
pharmaceutical manufacturers in Europe:
of UNITED KINGDOM
sales of £698.23 million [US$953.86 million]
of which 69%
(816.91 million Euros [US$988.99 million]
of which 46%
was X-rays), and
based in FRANCE
(938.34 million Euros [US$1.14 billion]
of which 59%
was Companion Animals).
Almirall SA reported sales of 855.34 million Euro (US$1.04 billion)
December of 2019.
increase of 13.0%
versus 2018, when the company's sales were 756.93 million Euro.
The sales level in 2019 was fairly close to the level five years ago: in 2014, Almirall SA had sales
of 786.40 million Euro.
Sales of Dermatology saw an increase
that was more than double the company's growth rate: sales were up
62.2% in 2019, from
109.88 million Euro to 178.18 million Euro.
Not all segments of Almirall SA experienced an increase in sales in 2019:
sales of R&d fell 57.0% to 925,000.00 Euro.
(However, this segment's sales were only a very small portion of the company's overall sales).
Almirall SA also experienced decreases in sales in
Corporate (down 1.2% to 25.63 million Euro)